Monopar Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Monopar Therapeutics Inc. (MNPR) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Operating Activities
Net Income-15.59-8.40-10.52-9.10-6.30-4.22
Stock Based Compensation1.141.901.641.471.320.00
Change in Working Capital3.49-1.351.650.320.440.20
Change in Accounts Payable0.51-1.331.480.400.450.00
Change in Other Working Capital2.98-0.020.17-0.090.000.00
Other Operating Activities4.551.901.641.471.081.01
Net Cash from Operating Activities-6.40-7.86-7.23-7.32-4.66-3.02
Investing Activities
Purchases of Investments-14.344.93-4.920.000.000.00
Sales/Maturities of Investments0.994.934.920.000.000.00
Other Investing Activities0.000.004.920.000.000.00
Net Cash from Investing Activities-14.344.93-4.920.000.000.00
Financing Activities
Common Stock Issued59.402.070.1111.288.1810.22
Common Stock Repurchased-0.10-0.05-0.08-0.060.000.00
Other Financing Activities-0.10-0.05-0.08-0.348.30-0.98
Net Cash from Financing Activities59.292.030.0310.888.189.35
Summary
Effect of Forex Changes on Cash0.00-0.020.000.000.00-0.01
Net Change in Cash38.55-0.90-12.113.573.086.33
Cash at Beginning of Period7.278.1920.3016.7413.216.89
Cash at End of Period45.827.278.1920.3016.7413.21
Free Cash Flow-6.40-7.86-7.23-7.32-4.66-3.02
Supplemental Disclosures
Income Taxes Paid0.000.000.000.00-0.010.00